SkyePharma's Flutiform meets asthma endpoint

SkyePharma (LSE:SKP) said Flutiform fluticasone/formoterol met the primary endpoint of a significant improvement in forced expiratory volume over one second (FEV1) vs. formoterol alone, fluticasone alone, and placebo in the Phase III SKY2028-3-004 trial. The double-blind, U.S. and European study enrolled in 557 patients with moderate-to-severe asthma. Flutiform met the primary endpoint in another Phase III trial in April (See BioCentury Extra, Wednesday, April 30, 2008). ...